• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

墨西哥局部青光眼治疗费用。

Topical glaucoma therapy cost in Mexico.

作者信息

Lazcano-Gomez Gabriel, Hernandez-Oteyza Alejandra, Iriarte-Barbosa María José, Hernandez-Garciadiego Carlos

机构信息

Asociación Para Evitar la Ceguera en México, I.A.P., Vicente Gacía Torres 46, Barrio San Lucas, CP 04030, Mexico, DF, Mexico.

出版信息

Int Ophthalmol. 2014 Apr;34(2):241-9. doi: 10.1007/s10792-013-9823-6. Epub 2013 Jul 12.

DOI:10.1007/s10792-013-9823-6
PMID:23846765
Abstract

Glaucoma is an important cause of irreversible blindness that represents a significant economic burden; most direct costs of glaucoma are drug-related. We calculated the annual cost of some of the most commonly prescribed glaucoma medications in Mexico, according to their average wholesale price (AWP) and dose regimen. Annual costs ranged from USD4.97 for Imot 15 ml (timolol 0.5 %; Laboratorios Sophia) to USD675.39 for Alphagan 5 ml (brimonidine 0.2 %; Allergan, Inc.). β-Blockers were the least expensive glaucoma medications (range USD20.44-55.44). Alphagan 5 ml was 250 % more expensive than other selective α(2)-agonists. Of the carbonic anhydrase inhibitors, dorzolamide 2 % was less expensive than brinzolamide 1 % (USD326.91 vs. USD418.96). The annual cost for prostaglandin analogs ranged from USD235.58 for bimatoprost 0.03 % to USD337.78 for latanoprost 0.005 %. Some fixed combinations were less expensive than separate combinations. The average annual cost for all treatments increased by 27.87 ± 10.09 % between 2009 and 2012. Annual glaucoma therapy cost seems to be lower in Mexico than in other countries, due to a lower AWP, especially for some medications made by Mexican laboratories.

摘要

青光眼是导致不可逆失明的重要原因,造成了巨大的经济负担;青光眼的大部分直接成本与药物相关。我们根据一些最常用青光眼药物的平均批发价(AWP)和给药方案,计算了其在墨西哥的年度成本。年度成本从Imot 15毫升(噻吗洛尔0.5%;Sophia实验室)的4.97美元到Alphagan 5毫升(酒石酸溴莫尼定0.2%;Allergan公司)的675.39美元不等。β受体阻滞剂是最便宜的青光眼药物(范围为20.44 - 55.44美元)。Alphagan 5毫升比其他选择性α(2)激动剂贵250%。在碳酸酐酶抑制剂中,2%的多佐胺比1%的布林佐胺便宜(326.91美元对418.96美元)。前列腺素类似物的年度成本从曲伏前列素0.03%的235.58美元到拉坦前列素0.005%的337.78美元不等。一些固定组合比单独组合便宜。2009年至2012年期间,所有治疗的平均年度成本增加了27.87 ± 10.09%。由于较低的平均批发价,尤其是墨西哥实验室生产的一些药物,墨西哥的青光眼年度治疗成本似乎低于其他国家。

相似文献

1
Topical glaucoma therapy cost in Mexico.墨西哥局部青光眼治疗费用。
Int Ophthalmol. 2014 Apr;34(2):241-9. doi: 10.1007/s10792-013-9823-6. Epub 2013 Jul 12.
2
Medical therapy cost considerations for glaucoma.青光眼的药物治疗成本考量
Am J Ophthalmol. 2003 Jul;136(1):18-25. doi: 10.1016/s0002-9394(03)00102-8.
3
Daily cost of glaucoma medications in China.中国青光眼药物的每日费用。
J Glaucoma. 2007 Oct-Nov;16(7):594-7. doi: 10.1097/IJG.0b013e318064c818.
4
Cost considerations of medical therapy for glaucoma.青光眼药物治疗的成本考量
Am J Ophthalmol. 1999 Oct;128(4):426-33. doi: 10.1016/s0002-9394(99)00235-4.
5
Cost analysis of glaucoma medications: a 3-year review.青光眼药物的成本分析:一项为期3年的综述。
J Glaucoma. 2002 Aug;11(4):354-8. doi: 10.1097/00061198-200208000-00013.
6
Cost analysis of glaucoma medications.青光眼药物的成本分析。
J Glaucoma. 2000 Apr;9(2):150-3. doi: 10.1097/00061198-200004000-00004.
7
Daily cost of ophthalmic solutions for treating glaucoma in Japan.日本治疗青光眼的眼科溶液的每日费用。
Jpn J Ophthalmol. 2001 Jan-Feb;45(1):99-102. doi: 10.1016/s0021-5155(00)00299-9.
8
Cost analysis of glaucoma medications.青光眼药物的成本分析
Am J Ophthalmol. 2008 Jan;145(1):106-13. doi: 10.1016/j.ajo.2007.08.041.
9
Comparative cost evaluation of brand name and generic ophthalmology medications in Ontario.安大略省品牌眼科药物和仿制药的成本比较评估。
Can J Ophthalmol. 2018 Apr;53(2):173-187. doi: 10.1016/j.jcjo.2017.08.003. Epub 2017 Sep 27.
10
Primary drug treatment for glaucoma: beta-blockers versus other medications.青光眼的主要药物治疗:β受体阻滞剂与其他药物对比
Surv Ophthalmol. 2002 Jan-Feb;47(1):63-73. doi: 10.1016/s0039-6257(01)00286-7.

引用本文的文献

1
Maximum Tolerated Medical Therapy for Glaucoma: Fixed-Dose Combinations of Timolol, Dorzolamide, Brimonidine with Latanoprost Versus Timolol, Dorzolamide with Latanoprost.青光眼的最大耐受药物治疗:噻吗洛尔、多佐胺、溴莫尼定与拉坦前列素的固定剂量组合对比噻吗洛尔、多佐胺与拉坦前列素。
Clin Ophthalmol. 2025 Aug 22;19:2913-2925. doi: 10.2147/OPTH.S540312. eCollection 2025.
2
From Eye Care to Hair Growth: Bimatoprost.从眼部护理到头发生长:比马前列素。
Pharmaceuticals (Basel). 2024 Apr 27;17(5):561. doi: 10.3390/ph17050561.
3
Effectiveness of Single-Tablet Combination Therapy in Improving Adherence and Persistence and the Relation to Clinical and Economic Outcomes.

本文引用的文献

1
Economic burden of glaucoma in Rivers State, Nigeria.尼日利亚河流州青光眼的经济负担
Clin Ophthalmol. 2012;6:2023-31. doi: 10.2147/OPTH.S37145. Epub 2012 Dec 5.
2
Cost Analysis of Medical versus Surgical Management of Glaucoma in Nigeria.尼日利亚青光眼药物治疗与手术治疗的成本分析
J Ophthalmic Vis Res. 2010 Oct;5(4):232-9.
3
An assessment of the health and economic burdens of glaucoma.青光眼的健康和经济负担评估。
单片复方疗法在提高依从性和持续性方面的有效性及其与临床和经济结果的关系。
J Health Econ Outcomes Res. 2024 Jan 23;11(1):8-22. doi: 10.36469/001c.91396. eCollection 2024.
4
A Worldwide Price Comparison of Glaucoma Medications, Laser Trabeculoplasty, and Trabeculectomy Surgery.全球青光眼药物、激光小梁成形术和小梁切除术的价格比较。
JAMA Ophthalmol. 2018 Nov 1;136(11):1271-1279. doi: 10.1001/jamaophthalmol.2018.3672.
5
A Phase III Randomized Clinical Trial of a 0.5% Timolol + 0.2% Brimonidine + 2.0% Dorzolamide Fixed Combination, Preservative-Free Ophthalmic Solution vs. 0.5% Timolol + 0.2% Brimonidine + 2.0% Dorzolamide Fixed Combination in Patients with Controlled Primary Open-Angle Glaucoma.一项0.5%噻吗洛尔+0.2%溴莫尼定+2.0%多佐胺固定复方无防腐剂滴眼液与0.5%噻吗洛尔+0.2%溴莫尼定+2.0%多佐胺固定复方治疗原发性开角型青光眼病情控制患者的III期随机临床试验
Ophthalmol Ther. 2018 Jun;7(1):145-156. doi: 10.1007/s40123-018-0128-8. Epub 2018 Apr 21.
6
Glaucoma Medication Preferences among Glaucoma Specialists in Mexico.墨西哥青光眼专家对青光眼药物的偏好
J Curr Glaucoma Pract. 2017 Sep-Dec;11(3):97-100. doi: 10.5005/jp-journals-10028-1232. Epub 2017 Oct 27.
Am J Ophthalmol. 2011 Oct;152(4):515-22. doi: 10.1016/j.ajo.2011.06.004.
4
Glaucoma costs in Denmark in treatment naive patients.丹麦未经治疗的青光眼患者的治疗费用。
Acta Ophthalmol. 2013 Feb;91(1):25-31. doi: 10.1111/j.1755-3768.2011.02212.x. Epub 2011 Aug 11.
5
A comprehensive perspective on patient adherence to topical glaucoma therapy.关于患者对局部青光眼治疗依从性的全面观点。
Ophthalmology. 2009 Nov;116(11 Suppl):S30-6. doi: 10.1016/j.ophtha.2009.06.024.
6
The cost-effectiveness of routine office-based identification and subsequent medical treatment of primary open-angle glaucoma in the United States.美国原发性开角型青光眼基于门诊的常规诊断及后续治疗的成本效益分析
Ophthalmology. 2009 May;116(5):823-32. doi: 10.1016/j.ophtha.2008.12.056. Epub 2009 Mar 14.
7
Cost analysis of glaucoma medications.青光眼药物的成本分析
Am J Ophthalmol. 2008 Jan;145(1):106-13. doi: 10.1016/j.ajo.2007.08.041.
8
Daily cost of glaucoma medications in China.中国青光眼药物的每日费用。
J Glaucoma. 2007 Oct-Nov;16(7):594-7. doi: 10.1097/IJG.0b013e318064c818.
9
Impact of visual field loss on health-related quality of life in glaucoma: the Los Angeles Latino Eye Study.视野缺损对青光眼患者健康相关生活质量的影响:洛杉矶拉丁裔眼病研究
Ophthalmology. 2008 Jun;115(6):941-948.e1. doi: 10.1016/j.ophtha.2007.08.037. Epub 2007 Nov 12.
10
Pharmacoeconomic analysis of prostaglandin and prostamide therapy for patients with glaucoma or ocular hypertension.前列腺素和前列腺酰胺治疗青光眼或高眼压症患者的药物经济学分析。
BMC Ophthalmol. 2007 Sep 27;7:16. doi: 10.1186/1471-2415-7-16.